Nivolumab/Ipilimumab Combo Yields Durable Efficacy in Advanced NSCLC

Frontline treatment with nivolumab plus ipilimumab induced durable and long-term efficacy, compared with chemotherapy, in patients with advanced non-small cell lung cancer, regardless of PD-L1 expression.

Source: CancerNetwork - May 30, 2020 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news